Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

February 05, 2021 By The ASCO Post Staff

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract OA01.04).

Related Content